Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

M. Moehler, J. Heo, H. C. Lee, W. Y. Tak, Y. Chao, S. W. Paik, H. J. Yim, K. S. Byun, A. Baron, G. Ungerechts, D. Jonker, L. Ruo, M. Cho, A. Kaubisch, H. Wege, P. Merle, O. Ebert, F. Habersetzer, J. F. Blanc, Olivier RosmorducR. Lencioni, R. Patt, A. M. Leen, F. Foerster, M. Homerin, N. Stojkowitz, M. Lusky, J. M. Limacher, M. Hennequi, N. Gaspar, B. McFadden, N. De Silva, D. Shen, A. Pelusio, D. H. Kirn, C. J. Breitbach, J. M. Burke

    Research output: Contribution to journalArticlepeer-review

    40 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)'. Together they form a unique fingerprint.

    Medicine & Life Sciences